EVENTS | VIEW CALENDAR
Galapagos and Roche initiate strategic alliance in COPD
MECHELEN, BelgiumóGalapagos NV announced in January that it has entered into a global, multi-year strategic alliance with Roche to develop potential new therapies in chronic obstructive pulmonary disease (COPD).
In the alliance, Galapagos will apply its target discovery platform to discover novel COPD targets. Galapagos is then responsible for the discovery and development of new small-molecule candidate drugs against these targets. Roche will have an exclusive option to license each small-molecule program after either clinical candidate selection or completion of Phase I clinical trials. In addition, Roche has an exclusive option to license the COPD targets for the discovery and development of antibodies against these targets. Upon exercise of each option, Roche will be responsible for the further preclinical development and commercialization.
Galapagos has received a research access payment of $8.3 million from Roche. Galapagos is also eligible to receive discovery, development, regulatory and sales milestone payments that could potentially exceed $557 million, plus royalties upon commercialization of any products covered in the agreement.
"This alliance with Roche on discovering novel COPD targets demonstrates the versatility of Galapagos' target discovery platform in identifying novel targets across a wide range of therapeutic areas. We are excited that this collaboration will focus on both antibodies and small molecules as potential drugs for COPD," says Onno van de Stolpe, CEO of Galapagos. "Roche's vast experience in developing and commercializing antibodies makes it the perfect partner for this combined approach."
"Galapagos' track record in discovering novel therapeutic targets and its drug discovery expertise make it an ideal partner for our COPD discovery program," says Satwant Narula, head of discovery for the inflammation area of Roche.